|Other names||Enteric Fever, slow fever|
|Causative agent: Salmonella enterica serological variant Typhi (shown under a microscope with flagellar stain)|
|Symptoms||Fever that starts low and increases daily, possibly reaching as high as 104.9 °F (40.5 °C) Headache, Weakness and fatigue, Muscle aches, Sweating, Dry cough, Loss of appetite and weight loss, Stomach pain, Diarrhea or constipation, Rash, Swollen stomach (enlarged liver or spleen)|
|Usual onset||1–2 weeks after ingestion|
|Duration||Usually 7–10 days after antibiotic treatment begins. Longer if there are complications or drug resistance|
|Causes||Gastrointestinal infection of Salmonella enterica serovar Typhi|
|Risk factors||Work in or travel to areas where typhoid fever is established, Work as a clinical microbiologist handling Salmonella typhi bacteria, Have close contact with someone who is infected or has recently been infected with typhoid fever, Drink water polluted by sewage that contains Salmonella typhi|
|Prevention||Preventable by vaccine. Travelers to regions with higher typhoid prevalence are usually encouraged to get a vaccination before travel.|
|Treatment||Antibiotics, hydration, surgery in extreme cases. Quarantine to avoid exposing others (not commonly done in modern times)|
|Prognosis||Likely to recover without complications if proper antibiotics administered and diagnosed early. If infecting strain is multi-drug resistant or extensively drug resistant then prognosis more difficult to determine.
Among untreated acute cases, 10% will shed bacteria for three months after initial onset of symptoms, and 2–5% will become chronic typhoid carriers.Some carriers are diagnosed by positive tissue specimen. Chronic carriers are by definition asymptomatic.
Typhoid fever, also known as typhoid, is a disease caused by Salmonella serotype Typhi bacteria. Symptoms may vary from mild to severe, and usually begin six to 30 days after exposure. Often there is a gradual onset of a high fever over several days. This is commonly accompanied by weakness, abdominal pain, constipation, headaches, and mild vomiting. Some people develop a skin rash with rose colored spots. In severe cases, people may experience confusion. Without treatment, symptoms may last weeks or months. Diarrhea is uncommon. Other people may carry the bacterium without being affected, but they are still able to spread the disease to others. Typhoid fever is a type of enteric fever, along with paratyphoid fever. So far, S. enterica Typhi is only known to infect and replicate within humans.
The cause is the bacterium Salmonella enterica subsp. enterica serovar Typhi growing in the intestines, peyers patches, mesenteric lymph nodes, spleen, liver, gallbladder, bone marrow and blood. Typhoid is spread by eating or drinking food or water contaminated with the feces from an infected person. Risk factors include limited access to clean drinking water, and poor sanitation. Those who have not yet been exposed to the pathogen and ingest contaminated drinking water or food are most at risk for developing symptoms. As far as we currently know, only humans can be infected; there are no known animal reservoirs.
Diagnosis is by culturing and identifying the Salmonella enterica Typhi bacterium from patient samples or detecting an immune response to the pathogen from blood samples. Recently, new advances in large-scale data collection and analysis are allowing researchers to develop better diagnostics - such as detecting changing abundances of small molecules in the blood that may specifically indicate typhoid fever. Diagnostic tools in regions where typhoid is most prevalent are quite limited in terms of accuracy and specificity; the time required for a proper diagnosis, increasing spread of antibiotic resistance, and the cost of testing is also a concern for under-resourced healthcare systems.
A typhoid vaccine can prevent about 40 to 90% of cases during the first two years. The vaccine may have some effect for up to seven years. For those at high risk or people traveling to areas where the disease is common, vaccination is recommended. Other efforts to prevent the disease include providing clean drinking water, good sanitation, and handwashing. Until an individual's infection is confirmed as cleared, the individual should not prepare food for others. The disease is treated with antibiotics such as azithromycin, fluoroquinolones, or third-generation cephalosporins. Resistance to these antibiotics has been developing, which has made treatment of the disease more difficult.
In 2015, 12.5 million new cases worldwide were reported. The disease is most common in India. Children are most commonly affected. Rates of disease decreased in the developed world in the 1940s as a result of improved sanitation and use of antibiotics to treat the disease. Each year in the United States, about 400 cases are reported and the disease occurs in an estimated 6,000 people. In 2015, it resulted in about 149,000 deaths worldwide – down from 181,000 in 1990 (about 0.3% of the global total). The risk of death may be as high as 20% without treatment. With treatment, it is between 1 and 4%.
Signs and symptoms
Classically, the progression of untreated typhoid fever is divided into three distinct stages, each lasting about a week. Over the course of these stages, the patient becomes exhausted and emaciated.
- In the first week, the body temperature rises slowly, and fever fluctuations are seen with relative bradycardia (Faget sign), malaise, headache, and cough. A bloody nose (epistaxis) is seen in a quarter of cases, and abdominal pain is also possible. A decrease in the number of circulating white blood cells (leukopenia) occurs with eosinopenia and relative lymphocytosis; blood cultures are positive for Salmonella enterica subsp. enterica serovar Typhi. The Widal test is usually negative in the first week.
- In the second week, the person is often too tired to get up, with high fever in plateau around 40 °C (104 °F) and bradycardia (sphygmothermic dissociation or Faget sign), classically with a dicrotic pulse wave. Delirium can occur, where the patient is often calm, but sometimes becomes agitated. This delirium has led to typhoid receiving the nickname "nervous fever". Rose spots appear on the lower chest and abdomen in around a third of patients. Rhonchi (rattling breathing sounds) are heard in the base of the lungs. The abdomen is distended and painful in the right lower quadrant, where a rumbling sound can be heard. Diarrhea can occur in this stage, but constipation is also common. The spleen and liver are enlarged (hepatosplenomegaly) and tender, and liver transaminases are elevated. The Widal test is strongly positive, with antiO and antiH antibodies. Blood cultures are sometimes still positive at this stage.
- In the third week of typhoid fever, a number of complications can occur:
- The fever is still very high and oscillates very little over 24 hours. Dehydration ensues along with malnutrition, and the patient is delirious (typhoid state). One-third of affected individuals develop a macular rash on the trunk.
- Intestinal haemorrhage due to bleeding in congested Peyer's patches occurs; this can be very serious, but is usually not fatal.
- Intestinal perforation in the distal ileum is a very serious complication and is frequently fatal. It may occur without alarming symptoms until septicaemia or diffuse peritonitis sets in.
- Respiratory diseases such as pneumonia and acute bronchitis
- Neuropsychiatric symptoms (described as "muttering delirium" or "coma vigil"), with picking at bedclothes or imaginary objects
- Metastatic abscesses, cholecystitis, endocarditis, and osteitis
- Low platelet count (thrombocytopenia) can sometimes be seen.
The Gram-negative bacterium that causes typhoid fever is Salmonella enterica subsp. enterica serovar Typhi. Based on MLST subtyping scheme, the two main sequence types of the S. Typhi are ST1 and ST2, which are currently widespread globally. The global phylogeographical analysis showed dominance of a haplotype 58 (H58) which probably originated in India during the late 1980s and is now spreading through the world carrying multidrug resistance. A more detailed genotyping scheme was reported in 2016 and is now being used widely. This scheme re-classified the nomenclature of H58 to genotype 4.3.1.
Unlike other strains of Salmonella, no animal carriers of typhoid are known. Humans are the only known carriers of the bacteria. S. enterica subsp. enterica serovar Typhi is spread through the fecal-oral route from individuals who are currently infected and from asymptomatic carriers of the bacteria. An asymptomatic human carrier is an individual who is still excreting typhoid bacteria in their stool a year after the acute stage of the infection.
Pathogenesis and Pathology
Diagnosis is made by any blood, bone marrow, or stool cultures and with the Widal test (demonstration of antibodies against Salmonella antigens O-somatic and H-flagellar). In epidemics and less wealthy countries, after excluding malaria, dysentery, or pneumonia, a therapeutic trial time with chloramphenicol is generally undertaken while awaiting the results of the Widal test and cultures of the blood and stool.
Widal test is used to identify specific antibodies in serum of people with typhoid by using antigen-antibody interactions.
In this test, the serum is mixed with a dead bacterial suspension of salmonella having specific antigens on it. If the patient's serum is carrying antibodies against those antigens then they get attached to them forming clumping which indicated the positivity of the test. If clumping does not occur then the test is negative. The Widal test is time-consuming and prone to significant false positive results. The test may also be falsely negative in the early course of illness. However, unlike the Typhidot test, the Widal test quantifies the specimen with titres.
Rapid diagnostic tests
Rapid diagnostic tests such as Tubex, Typhidot, and Test-It have shown moderate diagnostic accuracy.
The test is based on the presence of specific IgM and IgG antibodies to a specific 50Kd OMP antigen. This test is carried out on a cellulose nitrate membrane where a specific S. typhi outer membrane protein is attached as fixed test lines. It separately identifies IgM and IgG antibodies. IgM shows recent infection whereas IgG signifies remote infection.
The sample pad of this kit contains colloidal gold-anti-human IgG or gold-anti-human IgM. If the sample contains IgG and IgM antibodies against those antigens then they will react and get turned into red color. This complex will continue to move forward and the IgG and IgM antibodies will get attached to the first test line where IgG and IgM antigens are present giving a pink-purplish colored band. This complex will continue to move further and reach the control line which consists of rabbit anti-mouse antibody which bends the mouse anti-human IgG or IgM antibodies. The main purpose of the control line is to indicate a proper migration and reagent color. The typhidot test becomes positive within 2–3 days of infection.
Two colored bands indicate a positive test. Single-band of control line indicates a negative test. Single-band of first fixed line or no bands at all indicates invalid tests. The most important limitation of this test is that it is not quantitative and the result is only positive or negative.
Tubex test contains two types of particles brown magnetic particles coated with antigen and blue indicator particles coated with O9 antibody. During the test, if antibodies are present in the serum then they will get attached to the brown magnetic particles and settle down at the base and the blue indicator particles remain up in the solution giving a blue color that indicates positivity of the test.
If the serum does not have an antibody in it then the blue particle gets attached to the brown particles and settled down at the bottom giving no color to the solution which means the test is negative and they do not have typhoid.
Oral rehydration therapy
Where resistance is uncommon, the treatment of choice is a fluoroquinolone such as ciprofloxacin. Otherwise, a third-generation cephalosporin such as ceftriaxone or cefotaxime is the first choice. Cefixime is a suitable oral alternative.
Typhoid fever, when properly treated, is not fatal in most cases. Antibiotics, such as ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, amoxicillin, and ciprofloxacin, have been commonly used to treat typhoid fever. Treatment of the disease with antibiotics reduces the case-fatality rate to about 1%.
Without treatment, some patients develop sustained fever, bradycardia, hepatosplenomegaly, abdominal symptoms, and occasionally, pneumonia. In white-skinned patients, pink spots, which fade on pressure, appear on the skin of the trunk in up to 20% of cases. In the third week, untreated cases may develop gastrointestinal and cerebral complications, which may prove fatal in up to 10–20% of cases. The highest case fatality rates are reported in children under 4 years. Around 2–5% of those who contract typhoid fever become chronic carriers, as bacteria persist in the biliary tract after symptoms have resolved.
Surgery is usually indicated if intestinal perforation occurs. One study found a 30-day mortality rate of 9% (8/88), and surgical site infections at 67% (59/88), with the disease burden borne predominantly by low-resource countries.
For surgical treatment, most surgeons prefer simple closure of the perforation with drainage of the peritoneum. Small-bowel resection is indicated for patients with multiple perforations. If antibiotic treatment fails to eradicate the hepatobiliary carriage, the gallbladder should be resected. Cholecystectomy is sometimes successful, especially in patients with gallstones, but is not always successful in eradicating the carrier state because of persisting hepatic infection.
As resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and streptomycin is now common, these agents are no longer used as first–line treatment of typhoid fever. Typhoid resistant to these agents is known as multidrug-resistant typhoid.
Ciprofloxacin resistance is an increasing problem, especially in the Indian subcontinent and Southeast Asia. Many centres are shifting from using ciprofloxacin as the first line for treating suspected typhoid originating in South America, India, Pakistan, Bangladesh, Thailand, or Vietnam. For these people, the recommended first-line treatment is ceftriaxone. Also, azithromycin has been suggested to be better at treating resistant typhoid in populations than both fluoroquinolone drugs and ceftriaxone. Azithromycin can be taken by mouth and is less expensive than ceftriaxone which is given by injection.
A separate problem exists with laboratory testing for reduced susceptibility to ciprofloxacin; current recommendations are that isolates should be tested simultaneously against ciprofloxacin (CIP) and against nalidixic acid (NAL), and that isolates that are sensitive to both CIP and NAL should be reported as "sensitive to ciprofloxacin", but that isolates testing sensitive to CIP but not to NAL should be reported as "reduced sensitivity to ciprofloxacin". However, an analysis of 271 isolates showed that around 18% of isolates with a reduced susceptibility to fluoroquinolones, the class which CIP belongs, (MIC 0.125–1.0 mg/l) would not be picked up by this method.
In 2000, typhoid fever caused an estimated 21.7 million illnesses and 217,000 deaths. It occurs most often in children and young adults between 5 and 19 years old. In 2013, it resulted in about 161,000 deaths – down from 181,000 in 1990. Infants, children, and adolescents in south-central and Southeast Asia experience the greatest burden of illness. Outbreaks of typhoid fever are also frequently reported from sub-Saharan Africa and countries in Southeast Asia. In 2000, more than 90% of morbidity and mortality due to typhoid fever occurred in Asia. In the United States, about 400 cases occur each year, and 75% of these are acquired while traveling internationally.
Historically, before the antibiotic era, the case fatality rate of typhoid fever was 10–20%. Today, with prompt treatment, it is less than 1%. However, about 3–5% of individuals who are infected develop a chronic infection in the gall bladder. Since S. enterica subsp. enterica serovar Typhi is human-restricted, these chronic carriers become the crucial reservoir, which can persist for decades for further spread of the disease, further complicating the identification and treatment of the disease. Lately, the study of S. enterica subsp. enterica serovar Typhi associated with a large outbreak and a carrier at the genome level provides new insights into the pathogenesis of the pathogen.
In industrialized nations, water sanitation and food handling improvements have reduced the number of cases. Developing nations, such as those found in parts of Asia and Africa, have the highest rates of typhoid fever. These areas have a lack of access to clean water, proper sanitation systems, and proper health-care facilities. For these areas, such access to basic public-health needs is not in the near future.
In 2004–2005 an outbreak in the Democratic Republic of Congo resulted in more than 42,000 cases and 214 deaths. Since November 2016, Pakistan has had an outbreak of extensively drug-resistant (XDR) typhoid fever.
In Europe, a report based on data for 2017 retrieved from The European Surveillance System (TESSy) on the distribution of confirmed typhoid and paratyphoid fever cases found that 22 EU/EEA countries reported a total of 1,098 cases, 90.9% of which were travel-related, mainly acquired during travel to countries particularly in South Asia.
Sanitation and hygiene are important to prevent typhoid. It can only spread in environments where human feces are able to come into contact with food or drinking water. Careful food preparation and washing of hands are crucial to prevent typhoid. Industrialization, and in particular, the invention of the automobile, contributed greatly to the elimination of typhoid fever, as it eliminated the public-health hazards associated with having horse manure in public streets, which led to large number of flies, which are known as vectors of many pathogens, including Salmonella spp. According to statistics from the United States Centers for Disease Control and Prevention, the chlorination of drinking water has led to dramatic decreases in the transmission of typhoid fever in the United States.
Two typhoid vaccines are licensed for use for the prevention of typhoid: the live, oral Ty21a vaccine (sold as Vivotif by Crucell Switzerland AG) and the injectable typhoid polysaccharide vaccine (sold as Typhim Vi by Sanofi Pasteur and Typherix by GlaxoSmithKline). Both are efficacious and recommended for travellers to areas where typhoid is endemic. Boosters are recommended every five years for the oral vaccine and every two years for the injectable form. An older, killed whole-cell vaccine is still used in countries where the newer preparations are not available, but this vaccine is no longer recommended for use because it has a higher rate of side effects (mainly pain and inflammation at the site of the injection).
To help decrease rates of typhoid fever in developing nations, the World Health Organization (WHO) endorsed the use of a vaccination program starting in 1999. Vaccinations have proven to be a great way at controlling outbreaks in high incidence areas. Just as important, it is also very cost-effective. Vaccination prices are normally low, less than US$1 per dose. Because the price is low, poverty-stricken communities are more willing to take advantage of the vaccinations. Although vaccination programs for typhoid have proven to be effective, they alone cannot eliminate typhoid fever. Combining the use of vaccines with increasing public health efforts is the only proven way to control this disease.
Since the 1990s, two typhoid fever vaccines have been recommended by the WHO. The ViPS vaccine is given via injection, while the Ty21a is taken through capsules. Only people 2 years or older are recommended to be vaccinated with the ViPS vaccine, and it requires a revaccination after 2–3 years with a 55–72% vaccine efficacy. The alternative Ty21a vaccine is recommended for people 5 years or older, and has a 5-7-year duration with a 51–67% vaccine efficacy. The two different vaccines have been proven as a safe and effective treatment for epidemic disease control in multiple regions.
The plague of Athens, during the Peloponnesian War, was most likely an outbreak of typhoid fever. During the war, Athenians retreated into a walled-in city to escape attack from the Spartans. This massive influx of humans into a concentrated space overwhelmed the water supply and waste infrastructure, likely leading to unsanitary conditions as fresh water become harder to obtain and waste became more difficult to collect and remove beyond the city walls. In 2006, examining the remains for a mass burial site from Athens from around the time of the plague (~430 B.C.) revealed that fragments of DNA similar to modern day S. Typhi DNA were detected, whereas Yersinia pestis (plague), Rickettsia prowazekii (typhus), Mycobacterium tuberculosis, cowpox virus, and Bartonella henselae were not detected in any of the remains tested.
It is possible that the Roman emperor Augustus Caesar suffered from either a liver abscess or typhoid fever, and survived by using ice baths and cold compresses as a means of treatment for his fever. There is a statue of the Greek physician, Antonius Musa, who treated his fever.
Definition and evidence of transmission
The French doctors Pierre-Fidele Bretonneau and Pierre-Charles-Alexandre Louis are credited with describing typhoid fever as a specific disease, unique from typhus. Both doctors performed autopsies on individuals who died in Paris due to fever - and indicated that many had lesions on the Peyer's patches which correlated with distinct symptoms before death. British medics were skeptical of the differentiation between typhoid and typhus because both were endemic to Britain at that time. However, in France only typhoid was present circulating in the population. Pierre-Charlles-Alexandre Louis also performed case studies and statistical analysis to demonstrate that typhoid was contagious - and that persons who had not already had the disease seemed to be protected. Afterward, several American doctors confirmed these findings, and then Sir William Jenner convinced any remaining skeptics that typhoid is a specific disease recognizable by lesions in the Peyer's patches by examining sixty six autopsies from fever patients and concluding that the symptoms of headaches, diarrhea, rash spots, and abdominal pain were only present in patients which then had intestinal lesions after death; which solidified the association of the disease with the intestinal tract and gave the first clue to the route of transmission.
In 1847 William Budd learned of an epidemic of typhoid fever in Clifton, and identified that all 13 of 34 residents who had contracted the disease drew their drinking water from the same well. Notably, this observation was two years prior to John Snow discovering the route of contaminated water as the cause for a cholera outbreak. Budd later became health officer of Bristol and ensured a clean water supply, and documented further evidence of typhoid as a water-borne illness throughout his career.
Polish scientist Tadeusz Browicz described a short bacillus in the organs and feces of typhoid victims in 1874. Browicz was able to isolate and grow the bacilli but did not go as far as to insinuate or prove that they caused the disease.
In April 1880, three months prior to Eberth's publication, Edwin Klebs described short and filamentous bacilli in the Peyer's patches in typhoid victims. The bacterium's role in disease was speculated but not confirmed.
In 1880, Karl Joseph Eberth described a bacillus that he suspected was the cause of typhoid. Eberth is given credit for discovering the bacterium definitively by successfully isolating the same bacterium from 18 of 40 typhoid victims and failing to discover the bacterium present in any "control" victims of other diseases. In 1884, pathologist Georg Theodor August Gaffky (1850–1918) confirmed Eberth's findings. Gaffky isolated the same bacterium as Eberth from the spleen of a typhoid victim, and was able to grow the bacterium on solid media. The organism was given names such as Eberth's bacillus, Eberthella Typhi, and Gaffky-Eberth bacillus. Today, the bacillus that causes typhoid fever goes by the scientific name Salmonella enterica enterica, serovar Typhi.
Chlorination of water
Most developed countries had declining rates of typhoid fever throughout the first half of the 20th century due to vaccinations and advances in public sanitation and hygiene. In 1893 attempts were made to chlorinate the water supply in Hamburg, Germany and in 1897 Maidstone, England was the first town to have its entire water supply chlorinated. In 1905, following an outbreak of typhoid fever, the City of Lincoln, England instituted permanent water chlorination. The first permanent disinfection of drinking water in the US was made in 1908 to the Jersey City, New Jersey, water supply. Credit for the decision to build the chlorination system has been given to John L. Leal. The chlorination facility was designed by George W. Fuller.
Outbreaks in traveling military groups led to the creation of the Lyster bag in 1915; a bag with a faucet which can be hung from a tree or pole, filled with water, and comes with a chlorination tablet to drop into the water. The Lyster bag was essential for the survival of American soldiers in the Vietnam War.
Direct transmission and carriers
There were several occurrences of milk delivery men spreading typhoid fever throughout the communities they served. Although typhoid is not spread through milk itself, there were several examples of milk distributors in many locations watering their milk down with contaminated water, or cleaning the glass bottles the milk was placed in with contaminated water. Boston had two such cases around the turn of the 20th century. In 1899 there were 24 cases of typhoid traced to a single milkman, whose wife had died of typhoid fever a week before the outbreak. In 1908, J.J. Fallon, who was also a milkman, died of typhoid fever. Following his death and confirmation of the typhoid fever diagnosis, the city conducted an investigation of typhoid symptoms and cases along his route and found evidence of a significant outbreak. A month after the outbreak was first reported, the Boston Globe published a short statement declaring the outbreak over, stating "[a]t Jamaica Plain there is a slight increase, the total being 272 cases. Throughout the city there is a total of 348 cases." There was at least one death reported during this outbreak: Mrs. Sophia S. Engstrom, aged 46. Typhoid continued to ravage the Jamaica Plain neighborhood in particular throughout 1908, and several more people were reported dead due to typhoid fever, although these cases were not explicitly linked to the outbreak. The Jamaica Plain neighborhood at that time was home to many working-class and poor immigrants, mostly from Ireland.
The most notorious carrier of typhoid fever, but by no means the most destructive, was Mary Mallon, known as Typhoid Mary. Although other cases of human-to-human spread of typhoid were known at the time, the concept of an asymptomatic carrier, who was able to transmit disease, had only been hypothesized and not yet identified or proven. Mary Mallon became the first known example of an asymptomatic carrier of an infectious disease, making typhoid fever the first known disease being transmissible through asymptomatic hosts. The cases and deaths caused by Mary Mallon were mainly upper-class families in New York City. At the time of Mary's tenure as a personal cook for upper-class families, New York City reported 3,000 to 4,500 cases of typhoid fever annually. In the summer of 1906 two daughters of a wealthy family and maids working in their home became ill with typhoid fever. After investigating their home water sources and ruling out water contamination, the family hired civil engineer George Soper to conduct an investigation of the possible source of typhoid fever in the home. Soper described himself as an "epidemic fighter". His investigation ruled out many sources of food, and led him to question if the cook the family hired just prior to their household outbreak, Mallon, was the source. Since she had already left and begun employment elsewhere, he proceeded to track her down in order to obtain a stool sample. When he was able to finally meet Ms. Mallon in person he described her by saying "Mary had a good figure and might have been called athletic had she not been a little too heavy." In recounts of Soper's pursuit of Mallon, his only remorse appears to be that he was not given enough credit for his relentless pursuit and publication of her personal identifying information, stating that the media "rob[s] me of whatever credit belongs to the discovery of the first typhoid fever carrier to be found in America." Ultimately, 51 cases were suspected to be caused by Ms. Mallon and 3 deaths.
In 1924 the city of Portland, Oregon experienced an outbreak of typhoid fever, consisting of 26 cases and 5 deaths, all deaths due to intestinal hemorrhage. All cases were concluded to be due to a single milk farm worker, who was shedding large amounts of the typhoid pathogen in his urine. Misidentification of the disease, due to inaccurate Widal test results, delayed identification of the carrier and proper treatment. Ultimately, it took four samplings of different secretions from all of the dairy workers in order to successfully identify the carrier. Upon discovery, the dairy worker was forcibly quarantined for seven weeks, and regular samples were taken, most of the time the stool samples yielding no typhoid and often the urine yielding the pathogen. The carrier was reported as being 72 years old and appearing in excellent health with no symptoms. Pharmaceutical treatment decreased the amount of bacteria secreted, however, the infection was never fully cleared from the urine, and the carrier was released "under orders never again to engage in the handling of foods for human consumption." At the time of release, the authors noted "for more than fifty years he has earned his living chiefly by milking cows and knows little of other forms of labor, it must be expected that the closest surveillance will be necessary to make certain that he does not again engage in this occupation."
Overall, in the early 20th century the medical profession began to identify carriers of the disease, and evidence of transmission independent of water contamination. In a 1933 American Medical Association publication, physicians' treatment of asymptomatic carriers is best summarized by the opening line "Carriers of typhoid bacilli are a menace". Within the same publication, the first official estimate of typhoid carriers is given: 2 to 5% of all typhoid patients, and distinguished between temporary carriers and chronic carriers. The authors further estimate that there are 4 to 5 chronic female carriers to every one male carrier, although offered no data to explain this assertion of a gender difference in the rate of typhoid carriers. As far as treatment, the authors suggest: "When recognized, carriers must be instructed as to the disposal of excreta as well as to the importance of personal cleanliness. They should be forbidden to handle food or drink intended for others, and their movements and whereabouts must be reported to the public health officers".
Today, Typhoid carriers exist all over the world, but the highest incidence of asymptomatic infection is likely to occur in South/Southeast Asian and Sub-Saharan countries. The Los Angeles County department of public health tracks typhoid carriers and reports the number of carriers identified within the county yearly; between 2006 and 2016 0-4 new cases of typhoid carriers were identified per year. Cases of typhoid fever must be reported within one working day from identification. As of 2018, chronic typhoid carriers must sign a "Carrier Agreement" and are required to test for typhoid shedding twice yearly, ideally every 6 months. Carriers may be released from their agreements upon fulfilling "release" requirements, based on completion of a personalized treatment plan designed with medical professionals. Fecal or gallbladder carrier release requirements: 6 consecutive negative feces and urine specimens submitted at 1-month or greater intervals beginning at least 7 days after completion of therapy. Urinary or kidney carrier release requirements: 6 consecutive negative urine specimens submitted at 1-month or greater intervals beginning at least 7 days after completion of therapy. As of 2016 the male:female ratio of carriers in Los Angeles county was 3:1.
Due to the nature of asymptomatic cases, many questions remain about how individuals are able to tolerate infection for long periods of time, how to identify such cases, and efficient options for treatment. Researchers are currently working to understand asymptomatic infection with Salmonella species by studying infections in laboratory animals, which will ultimately lead to improved prevention and treatment options for typhoid carriers. In 2002, Dr. John Gunn described the ability of Salmonella sp. to form biofilms on gallstones in mice, providing a model for studying carriage in the gallbladder. Dr. Denise Monack and Dr. Stanley Falkow described a mouse model of asymptomatic intestinal and systemic infection in 2004, and Dr. Monack went on to demonstrate that a sub-population of superspreaders are responsible for the majority of transmission to new hosts, following the 80/20 rule of disease transmission, and that the intestinal microbiota likely plays a role in transmission.  Dr. Monack's mouse model allows long-term carriage of salmonella in mesenteric lymph nodes, spleen and liver.
British bacteriologist Almroth Edward Wright first developed an effective typhoid vaccine at the Army Medical School in Netley, Hampshire. It was introduced in 1896 and used successfully by the British during the Second Boer War in South Africa. At that time, typhoid often killed more soldiers at war than were lost due to enemy combat. Wright further developed his vaccine at a newly opened research department at St Mary's Hospital Medical School in London from 1902, where he established a method for measuring protective substances (opsonin) in human blood. Wright's version of the typhoid vaccine was produced by growing the bacterium at body temperature in broth, then heating the bacteria to 60 °C to "heat inactivate" the pathogen, killing it, while keeping the surface antigens intact. The heat-killed bacteria was then injected into a patient. To show evidence of the vaccine's efficacy, Wright then collected serum samples from patients several weeks post-vaccination, and tested their serum's ability to agglutinate live typhoid bacteria. A "positive" result was represented by clumping of bacteria, indicating that the body was producing anti-serum (now called antibodies) against the pathogen.
Citing the example of the Second Boer War, during which many soldiers died from easily preventable diseases, Wright convinced the British Army that 10 million vaccine doses should be produced for the troops being sent to the Western Front, thereby saving up to half a million lives during World War I. The British Army was the only combatant at the outbreak of the war to have its troops fully immunized against the bacterium. For the first time, their casualties due to combat exceeded those from disease.
In 1909, Frederick F. Russell, a U.S. Army physician, adopted Wright's typhoid vaccine for use with the Army, and two years later, his vaccination program became the first in which an entire army was immunized. It eliminated typhoid as a significant cause of morbidity and mortality in the U.S. military. Typhoid vaccination for members of the American military became mandatory in 1911. Before the vaccine, the rate of typhoid fever in the military was 14,000 or greater per 100,000 soldiers. By World War I, the rate of typhoid in American soldiers was 37 per 100,000.
In 1934, discovery of the Vi capsular antigen by Arthur Felix and Miss S. R. Margaret Pitt enabled development of the safer Vi Antigen vaccine - which is widely in use today. Arthur Felix and Margaret Pitt also isolated the strain Ty2, which became the parent strain of Ty21a, the strain used as a live-attenuated vaccine for typhoid fever today.
Antibiotics and resistance
Chloramphenicol was isolated from Streptomyces by Dr. David Gotlieb during the 1940s. In 1948 American army doctors tested its efficacy in treating typhoid patients in Kuala Lumpur, Malaysia. Individuals who received a full course of treatment cleared the infection, whereas patients given a lower dose suffered a relapse. Importantly, asymptomatic carriers continued to shed bacilli despite chloramphenicol treatment - only ill patients were improved with chloramphenicol. Resistance to chloramphenicol became frequent in Southeast Asia by the 1950s, and today chloramphenicol is only used as a last resort due to the high prevalence of resistance.
The disease has been referred to by various names, often associated with symptoms, such as gastric fever, enteric fever, abdominal typhus, infantile remittant fever, slow fever, nervous fever, pythogenic fever, drain fever and low fever.
- Emperor Augustus of Rome (suspected based on historical record but not confirmed), survived.
- Albert, Prince Consort, husband of Queen Victoria of the United Kingdom, died in 24 days after first record of "feeling horribly ill". Died 14 December 1861 after suffering loss of appetite, insomnia, fever, chills, profuse sweating, vomiting, rash spots, delusions, inability to recognize family members, worsening rash on abdomen, a change in tongue color, then finally a state of extreme fatigue. Attending physician William Jenner, an expert on Typhoid fever at the time, diagnosed him.
- Edward VII of the UK, son of Queen Victoria, while still Prince of Wales, had a near fatal case of typhoid fever.
- Tsar Nicholas II of Russia, survived, illness was circa 1900-1901.[self-published source]
- William Henry Harrison, the 9th President of the United States of America, died 32 days into his term, in 1841. This is the shortest term served by a United States President.
- Stephen A. Douglas, political opponent of Abraham Lincoln in 1858 and 1860, died of typhoid on June 3, 1861.
- Ignacio Zaragoza, Mexican general and politician, died at the age of 33 of typhoid fever on September 8, 1862.
- William Wallace Lincoln, the son of US president Abraham and Mary Todd Lincoln, died of typhoid in 1862.
- Martha Bulloch Roosevelt, mother of president Theodore Roosevelt and paternal grandmother of Eleanor Roosevelt, died of typhoid fever in 1884.
- Mary Mallon, "Typhoid Mary" - see history section, "carriers" for further details
- Leland Stanford Jr., son of American tycoon and politician A. Leland Stanford and eponym of Leland Stanford Junior University, died of typhoid fever in 1884 at the age of 15.
- Three of Louis Pasteur's five children died of typhoid fever.
- Gerard Manley Hopkins, English poet, died of typhoid fever in 1889.
- Lizzie van Zyl, South African child inmate of the Bloemfontein concentration camp during the Second Boer War, died of typhoid fever in 1901.
- Dr HJH 'Tup' Scott, captain of the 1886 Australian cricket team that toured England, died of typhoid in 1910.
- Arnold Bennett, English novelist, died in 1932 of typhoid, two months after drinking a glass of water in a Paris hotel to prove it was safe.
- Hakaru Hashimoto, Japanese medical scientist, died of typhoid fever in 1934.
- Plague of Athens (suspected)
- "Burning Fever" outbreak among indigenous Americans. Between 1607-1624, 85% of the population at the James River died from a typhoid epidemic. The World Health Organization estimates the death toll was over 6,000 during this time. 
- Maidstone, Kent outbreak in 1897-1898: 1,847 patients were recorded to have typhoid fever. This outbreak is notable because it was the first time a typhoid vaccine was deployed during a civilian outbreak. Almoth Edward Wright's vaccine was offered to 200 healthcare providers, and of the 84 individuals who received the vaccine none developed typhoid whereas 4 who had not been vaccinated became ill.
- American army in the Spanish-American war: government records estimate over 21,000 troops suffered from typhoid, resulting in 2,200 deaths.
- In 1902, guests at mayoral banquets in Southampton and Winchester, England, became ill and four died, including the Dean of Winchester, after consuming oysters. The infection was due to oysters sourced from Emsworth, where the oyster beds had been contaminated with raw sewage.
- Jamaica Plain neighborhood, Boston in 1908 - linked to milk delivery. See history section, "carriers" for further details. 
- Outbreak in upperclass New Yorkers who employed Mary Mallon - 51 cases and 3 deaths from 1907 to 1915.
- Aberdeen, Scotland in summer 1964 - traced back to contaminated canned beef sourced from Argentina sold in markets. More than 500 patients were quarantined in the hospital for a minimum of four weeks, and the outbreak was contained without any deaths. 
- Dushanbe, Tajikstan in 1996 - 1997: 10,677 cases reported, 108 deaths 
- Kinshasa, Democratic Republic of the Congo in 2004: 43,000 cases and over 200 deaths. A prospective study of specimens collected in the same region between 2007 and 2011 revealed about one third of samples obtained from patient samples were resistant to multiple antibiotics.
- Kampala, Uganda in 2015: 10,230 cases reported
- Acute Communicable Disease Control, 2016 Annual Morbidity Report (2016). "TYPHOID FEVER, ACUTE AND CARRIER" (PDF). Los Angeles County Department of Public Health. p. 133.
- Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL (March 2015). "Typhoid fever". Lancet. 385 (9973): 1136–45. doi:10.1016/s0140-6736(13)62708-7. PMID 25458731. S2CID 2409150.
- Newton AE (2014). "3 Infectious Diseases Related To Travel". CDC health information for international travel 2014: the yellow book. ISBN 9780199948499. Archived from the original on 2015-07-02.
- "Typhoid Fever". cdc.gov. May 14, 2013. Archived from the original on 6 June 2016. Retrieved 28 March 2015.
- "Typhoid Fever". cdc.gov. May 14, 2013. Archived from the original on 2 April 2015. Retrieved 28 March 2015.
- "Typhoid vaccines: WHO position paper" (PDF). Relevé Épidémiologique Hebdomadaire. 83 (6): 49–59. February 2008. PMID 18260212. Archived (PDF) from the original on April 2, 2015.
- Pitzer VE, Meiring J, Martineau FP, Watson CH, Kang G, Basnyat B, Baker S (October 2019). "The Invisible Burden: Diagnosing and Combatting Typhoid Fever in Asia and Africa". Clinical Infectious Diseases. 69 (Suppl 5): S395–S401. doi:10.1093/cid/ciz611. PMC 6792124. PMID 31612938.
- Crump JA, Mintz ED (January 2010). "Global trends in typhoid and paratyphoid Fever". Clinical Infectious Diseases. 50 (2): 241–6. doi:10.1086/649541. PMC 2798017. PMID 20014951.
- Näsström E, Parry CM, Thieu NT, Maude RR, de Jong HK, Fukushima M, et al. (2017). Reproducible diagnostic metabolites in plasma from typhoid fever patients in Asia and Africa. Umeå universitet, Kemiska institutionen. OCLC 1234663430.
- Milligan R, Paul M, Richardson M, Neuberger A (May 2018). "Vaccines for preventing typhoid fever". The Cochrane Database of Systematic Reviews. 5: CD001261. doi:10.1002/14651858.CD001261.pub4. PMC 6494485. PMID 29851031.
- Chatham-Stephens K, Medalla F, Hughes M, Appiah GD, Aubert RD, Caidi H, et al. (January 2019). "Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018". MMWR. Morbidity and Mortality Weekly Report. 68 (1): 11–13. doi:10.15585/mmwr.mm6801a3. PMC 6342547. PMID 30629573.
- Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- Jackson BR, Iqbal S, Mahon B (March 2015). "Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015". MMWR. Morbidity and Mortality Weekly Report. 64 (11): 305–8. PMC 4584884. PMID 25811680.
- Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality and Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- Abubakar II, Tillmann T, Banerjee A, et al. (GBD 2013 Mortality and Causes of Death Collaborators) (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
- Cunha BA (March 2004). "Osler on typhoid fever: differentiating typhoid from typhus and malaria". Infectious Disease Clinics of North America. 18 (1): 111–25. doi:10.1016/S0891-5520(03)00094-1. PMID 15081508.
- Evans, Alfred S.; Brachman, Philip S. (2013). Bacterial Infections of Humans: Epidemiology and Control. Springer. p. 839. ISBN 978-1-4615-5327-4.
- "Typhoid". Merriam Webster Dictionary. Archived from the original on 2013-07-02. Retrieved 2013-06-24.
- Kumar P, Kumar R (March 2017). "Enteric Fever". Indian Journal of Pediatrics. 84 (3): 227–230. doi:10.1007/s12098-016-2246-4. PMID 27796818. S2CID 3825885.
- "Typhoid fever: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-04-21.
- Yap KP, Ho WS, Gan HM, Chai LC, Thong KL (2016). "Global MLST of Salmonella Typhi Revisited in Post-genomic Era: Genetic Conservation, Population Structure, and Comparative Genomics of Rare Sequence Types". Frontiers in Microbiology. 7: 270. doi:10.3389/fmicb.2016.00270. PMC 4774407. PMID 26973639.
- Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. (June 2015). "Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events". Nature Genetics. 47 (6): 632–9. doi:10.1038/ng.3281. PMC 4921243. PMID 25961941.
- Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, et al. (October 2016). "An extended genotyping framework for Salmonella enterica serovar Typhi, the cause of human typhoid". Nature Communications. 7 (1): 12827. Bibcode:2016NatCo...712827W. doi:10.1038/ncomms12827. PMC 5059462. PMID 27703135.
- Eng SK, Pusparajah P, Ab Mutalib NS, Ser HL, Chan KG, Lee LH (June 2015). "Salmonella:A review on pathogenesis, epidemiology and antibiotic resistance". Frontiers in Life Science. 8 (3): 284–293. doi:10.1080/21553769.2015.1051243.
- Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN 978-0-8385-8529-0.
- Feasey NA, Gordon MA (2014). "Salmonella Infections". In Farrar J, Hotez P, Junghanss T, Kang G, Lalloo D, White NJ (eds.). Manson's Tropical Infectious Diseases (23rd ed.). Saunders Ltd. pp. 337–348.e2. doi:10.1016/B978-0-7020-5101-2.00026-1. ISBN 9780702051012.
- Wijedoru L, Mallett S, Parry CM, et al. (Cochrane Infectious Diseases Group) (May 2017). "Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever". The Cochrane Database of Systematic Reviews. 5: CD008892. doi:10.1002/14651858.CD008892.pub2. PMC 5458098. PMID 28545155.
- Lim PL, Tam FC, Cheong YM, Jegathesan M (August 1998). "One-step 2-minute test to detect typhoid-specific antibodies based on particle separation in tubes". Journal of Clinical Microbiology. 36 (8): 2271–8. doi:10.1128/JCM.36.8.2271-2278.1998. PMC 105030. PMID 9666004.
- "TYPHIDOT Rapid IgG/IgM (Combo)" (PDF). Reszon Diagnostics International. Retrieved 14 November 2019.
- "UpToDate". www.uptodate.com. Retrieved 2020-04-21.
- Parry CM, Beeching NJ (June 2009). "Treatment of enteric fever". BMJ. 338: b1159. doi:10.1136/bmj.b1159. PMID 19493937. S2CID 3264721.
- Effa EE, Lassi ZS, Critchley JA, Garner P, Sinclair D, Olliaro PL, Bhutta ZA (October 2011). "Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)". The Cochrane Database of Systematic Reviews (10): CD004530. doi:10.1002/14651858.CD004530.pub4. PMC 6532575. PMID 21975746.
- Soe GB, Overturf GD (1987). "Treatment of typhoid fever and other systemic salmonelloses with cefotaxime, ceftriaxone, cefoperazone, and other newer cephalosporins". Reviews of Infectious Diseases. 9 (4): 719–36. doi:10.1093/clinids/9.4.719. JSTOR 4454162. PMID 3125577.
- Wallace MR, Yousif AA, Mahroos GA, Mapes T, Threlfall EJ, Rowe B, Hyams KC (December 1993). "Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever". European Journal of Clinical Microbiology & Infectious Diseases. 12 (12): 907–10. doi:10.1007/BF01992163. PMID 8187784. S2CID 19358454.
- Dutta P, Mitra U, Dutta S, De A, Chatterjee MK, Bhattacharya SK (June 2001). "Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children". The Indian Journal of Medical Research. 113: 210–3. PMID 11816954.
- Коваленко АН, et al. (2011). "Особенности клиники, диагностики и лечения брюшного тифа у лиц молодого возраста". Voen.-meditsinskii Zhurnal. 332 (1): 33–39.
- Bhutta ZA, Khan IA, Molla AM (November 1994). "Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone". The Pediatric Infectious Disease Journal. 13 (11): 990–4. doi:10.1097/00006454-199411000-00010. PMID 7845753.
- Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM (March 1999). "A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group". The Pediatric Infectious Disease Journal. 18 (3): 245–8. doi:10.1097/00006454-199903000-00007. PMID 10093945.
- Baron S et al.
- "Diarrhoeal Diseases (Updated February 2009)". Archived from the original on November 2, 2011. Retrieved 2013-04-25.. World Health Organization
- "WHO | Typhoid fever". www.who.int. Archived from the original on 2017-07-27. Retrieved 2017-08-10.
- Anyomih TK, Drake TM, Glasbey J, Fitzgerald JE, Ots R, et al. (GlobalSurg Collaborative) (October 2018). "Management and Outcomes Following Surgery for Gastrointestinal Typhoid: An International, Prospective, Multicentre Cohort Study". World Journal of Surgery. 42 (10): 3179–3188. doi:10.1007/s00268-018-4624-8. PMC 6132852. PMID 29725797.
- Waddington CS, Darton TC, Pollard AJ (January 2014). "The challenge of enteric fever". The Journal of Infection. Hot Topics in Infection and Immunity in Children - Papers from the 10th annual IIC meeting, Oxford, UK, 2012. 68 Suppl 1: S38-50. doi:10.1016/j.jinf.2013.09.013. PMID 24119827.
- Gonzalez-Escobedo G, Marshall JM, Gunn JS (January 2011). "Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state". Nature Reviews. Microbiology. 9 (1): 9–14. doi:10.1038/nrmicro2490. PMC 3255095. PMID 21113180.
- "Extensively Drug-Resistant Typhoid Fever in Pakistan - Watch - Level 1, Practice Usual Precautions - Travel Health Notices | Travelers' Health | CDC". wwwnc.cdc.gov. Retrieved 2020-04-21.
- Zaki SA, Karande S (May 2011). "Multidrug-resistant typhoid fever: a review". Journal of Infection in Developing Countries. 5 (5): 324–37. doi:10.3855/jidc.1405. PMID 21628808.
- Gibani MM, Britto C, Pollard AJ (October 2018). "Typhoid and paratyphoid fever: a call to action". Current Opinion in Infectious Diseases. 31 (5): 440–448. doi:10.1097/QCO.0000000000000479. PMC 6319573. PMID 30138141.
- Cooke FJ, Wain J, Threlfall EJ (August 2006). "Fluoroquinolone resistance in Salmonella Typhi". BMJ. 333 (7563): 353–4. doi:10.1136/bmj.333.7563.353-b. PMC 1539082. PMID 16902221.
- "Typhoid Fever". World Health Organization. Archived from the original on 2011-11-02. Retrieved 2007-08-28.
- Crump JA, Luby SP, Mintz ED (May 2004). "The global burden of typhoid fever". Bulletin of the World Health Organization. 82 (5): 346–53. PMC 2622843. PMID 15298225.
- Muyembe-Tamfum JJ, Veyi J, Kaswa M, Lunguya O, Verhaegen J, Boelaert M (January 2009). "An outbreak of peritonitis caused by multidrug-resistant Salmonella Typhi in Kinshasa, Democratic Republic of Congo". Travel Medicine and Infectious Disease. 7 (1): 40–3. doi:10.1016/j.tmaid.2008.12.006. PMID 19174300.
- Baddam R, Kumar N, Thong KL, Ngoi ST, Teh CS, Yap KP, et al. (July 2012). "Genetic fine structure of a Salmonella enterica serovar Typhi strain associated with the 2005 outbreak of typhoid fever in Kelantan, Malaysia". Journal of Bacteriology. 194 (13): 3565–6. doi:10.1128/jb.00581-12. PMC 3434757. PMID 22689247.
- Yap KP, Teh CS, Baddam R, Chai LC, Kumar N, Avasthi TS, et al. (September 2012). "Insights from the genome sequence of a Salmonella enterica serovar Typhi strain associated with a sporadic case of typhoid fever in Malaysia". Journal of Bacteriology. 194 (18): 5124–5. doi:10.1128/jb.01062-12. PMC 3430317. PMID 22933756.
- "WHO | A study of typhoid fever in five Asian countries: Disease burden and implications for controls".
- Matano LM, Morris HG, Wood BM, Meredith TC, Walker S (December 2016). "Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening". Bioorganic & Medicinal Chemistry. 24 (24): 6307–6314. doi:10.1016/j.bmc.2016.08.003. PMC 5180449. PMID 27594549.
- "Typhoid Fever" (PDF). Florida Department of Health. December 23, 2013.
- Heymann, David L., ed. (2008), Control of Communicable Diseases Manual, Washington, D.C.: American Public Health Association, pg 665. ISBN 978-0-87553-189-2.
- Levine MM, Black RE, Lanata C (December 1982). "Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area". The Journal of Infectious Diseases. 146 (6): 724–6. doi:10.1093/infdis/146.6.724. PMID 7142746.
- Yap KP, Gan HM, Teh CS, Baddam R, Chai LC, Kumar N, et al. (November 2012). "Genome sequence and comparative pathogenomics analysis of a Salmonella enterica Serovar Typhi strain associated with a typhoid carrier in Malaysia". Journal of Bacteriology. 194 (21): 5970–1. doi:10.1128/jb.01416-12. PMC 3486090. PMID 23045488.
- Yap KP, Gan HM, Teh CS, Chai LC, Thong KL (November 2014). "Comparative genomics of closely related Salmonella enterica serovar Typhi strains reveals genome dynamics and the acquisition of novel pathogenic elements". BMC Genomics. 15 (1): 1007. doi:10.1186/1471-2164-15-1007. PMC 4289253. PMID 25412680.
- Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM (October 2015). "Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections". Clinical Microbiology Reviews. 28 (4): 901–37. doi:10.1128/CMR.00002-15. PMC 4503790. PMID 26180063.
- Khan MI, Pach A, Khan GM, Bajracharya D, Sahastrabuddhe S, Bhutta W, et al. (June 2015). "Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan". Vaccine. 33 Suppl 3: C62-7. doi:10.1016/j.vaccine.2015.03.087. PMID 25937612.
- "Extensively Drug-Resistant Typhoid Fever in Pakistan". Centers for Disease Control and Prevention. 30 September 2019.
- "Typhoid and paratyphoid fevers: Annual Epidemiological Report for 2017" (PDF). European Centre for Disease Prevention and Control. October 2020. Retrieved 20 July 2021.
- "The Great Horse Manure Crisis of 1894". Archived from the original on 2015-05-25.
- Cirillo VJ (2006). ""Winged sponges": houseflies as carriers of typhoid fever in 19th- and early 20th-century military camps". Perspectives in Biology and Medicine. 49 (1): 52–63. doi:10.1353/pbm.2006.0005. PMID 16489276. S2CID 41428479.
- "History of Drinking Water Treatment | Drinking Water | Healthy Water | CDC". www.cdc.gov. 2018-10-10. Retrieved 2020-04-21.
- Marathe SA, Lahiri A, Negi VD, Chakravortty D (2012). "Typhoid fever & vaccine development: a partially answered question". The Indian Journal of Medical Research. 135 (2): 161–9. PMC 3336846. PMID 22446857.
- Date KA, Bentsi-Enchill A, Marks F, Fox K (June 2015). "Typhoid fever vaccination strategies". Vaccine. 33 Suppl 3: C55-61. doi:10.1016/j.vaccine.2015.04.028. PMID 25902360.
- "Vivaxim Solution for injection". NPS MedicineWise. Archived from the original on 1 October 2015. Retrieved 10 April 2017.
- Gallagher J (4 December 2019). "Typhoid vaccine 'works fantastically well'". BBC News. Retrieved 17 January 2020.
- Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, et al. (December 2019). "Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal". The New England Journal of Medicine. 381 (23): 2209–2218. doi:10.1056/NEJMoa1905047. PMC 6785806. PMID 31800986.
- Adler R (2016). Typhoid fever : a history. Elise Mara. Jefferson, North Carolina. ISBN 978-0-7864-9781-2. OCLC 934938999.
- Papagrigorakis MJ, Yapijakis C, Synodinos PN, Baziotopoulou-Valavani E (May 2006). "DNA examination of ancient dental pulp incriminates typhoid fever as a probable cause of the Plague of Athens". International Journal of Infectious Diseases. 10 (3): 206–14. doi:10.1016/j.ijid.2005.09.001. PMID 16412683.
- Stachura J, Gałazka K (December 2003). "History and current status of Polish gastroenterological pathology". Journal of Physiology and Pharmacology. 54 Suppl 3: 183–92. PMID 15075472.
- "Typhoid Fever Considered as a Problem of Scientific Medicine". JAMA: The Journal of the American Medical Association. 71 (10): 847. 1918-09-07. doi:10.1001/jama.1918.02600360063023. hdl:2027/coo1.ark:/13960/t9d516735. ISSN 0098-7484.
- Eberth CJ (1880). "Die Organismen in den Organen bei Typhus abdominalis" [Organisms in the [internal] organs in cases of Typhus abdominalis]. Archiv für pathologische Anatomie und Physiologie (in German). 81: 58–74.
- Eberth CJ (1881). "Neue Untersuchungen über den Bacillus des Abdominaltyphus" [New investigations into the bacilli of abdominal typhoid]. Archiv für pathologische Anatomie und Physiologie (in German). 83: 486–501.
- Eberth's findings were verified by Robert Koch Koch R (1881). "Zur Untersuchung von pathogenen Organismen" [On the investigation of pathogenic organisms]. Mitteilungen aus dem Kaiserlichen Gesundheitsamte (in German). 1: 1–49. Archived from the original on 2017-04-23.
- Gaffky G (1884). "Zur aetiologie des abdominaltyphus" [On the etiology of abdominal typhus]. Mitteillungen aus dem Kaiserlichen Gesundheitsamt (in German). 2: 372–420. Archived from the original on 2017-04-23.
- Wertheim HF, Horby P, Woodall JP (2012). Atlas of Human Infectious Diseases (1st ed.). New York, NY: John Wiley & Sons. ISBN 978-1-4443-5467-6. OCLC 897547171.
- "Typhoid Epidemic at Maidstone". Journal of the Sanitary Institute. 18: 388. October 1897.
- "A miracle for public health?". Retrieved 2012-12-17.
- Leal JL (1909). "The Sterilization Plant of the Jersey City Water Supply Company at Boonton, N.J.". Proceedings American Water Works Association. pp. 100–9.
- Fuller GW (1909). "Description of the Process and Plant of the Jersey City Water Supply Company for the Sterilization of the Water of the Boonton Reservoir.". Proceedings American Water Works Association. pp. 110–34.
- "Typhoid Milkman". Remember Jamaica Plain?. 2007-11-05. Retrieved 2021-06-24.
- Von Hoffman A (1996). Local attachments : the making of an American urban neighborhood, 1850 to 1920. Johns Hopkins University Press. OCLC 1036707621.
- "Nova: The Most Dangerous Woman in America". Archived from the original on 2010-04-26.
- "Short Wave: Typhoid Mary: Lessons From An Infamous Quarantine on Apple Podcasts". Apple Podcasts. Retrieved 2021-06-28.
- Soper GA (October 1939). "The Curious Career of Typhoid Mary". Bulletin of the New York Academy of Medicine. 15 (10): 698–712. ISSN 0028-7091. PMC 1911442. PMID 19312127.
- Klein C. "10 Things You May Not Know About 'Typhoid Mary'". HISTORY. Retrieved 2021-06-28.
- Sears HJ, Garhart RW, Mack DW (October 1924). "A Milk Borne Epidemic of Typhoid Fever Traced to a Urinary Carrier". American Journal of Public Health. 14 (10): 848–54. doi:10.2105/ajph.14.10.848. PMC 1355026. PMID 18011334.
- "Typhoid Carriers and Their Treatment". Journal of the American Medical Association. 100 (23): 1866. 1933-06-10. doi:10.1001/jama.1933.02740230044012. ISSN 0002-9955.
- Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. (April 2019). "The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017". The Lancet. Infectious Diseases. 19 (4): 369–381. doi:10.1016/S1473-3099(18)30685-6. PMC 6437314. PMID 30792131.
- Los Angeles Department of Public Health, Acute Communicable Disease Control Manual (B-73) (June 2018). "Typhoid Fever Carrier" (PDF). LA County Public Health, Acute Communicable Disease Control Manual. Retrieved June 27, 2021.
- Prouty AM, Schwesinger WH, Gunn JS (May 2002). "Biofilm formation and interaction with the surfaces of gallstones by Salmonella spp". Infection and Immunity. 70 (5): 2640–9. doi:10.1128/iai.70.5.2640-2649.2002. PMC 127943. PMID 11953406.
- Monack DM, Bouley DM, Falkow S (January 2004). "Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization". The Journal of Experimental Medicine. 199 (2): 231–41. doi:10.1084/jem.20031319. PMC 2211772. PMID 14734525.
- Lawley TD, Bouley DM, Hoy YE, Gerke C, Relman DA, Monack DM (January 2008). "Host transmission of Salmonella enterica serovar Typhimurium is controlled by virulence factors and indigenous intestinal microbiota". Infection and Immunity. 76 (1): 403–16. doi:10.1128/iai.01189-07. PMC 2223630. PMID 17967858.
- "Sir Almroth Edward Wright". Encyclopædia Britannica. Archived from the original on 2013-11-11.
- Wright AE, Douglas SR (1904-01-31). "An experimental investigation of the rôle of the blood fluids in connection with phagocytosis". Proceedings of the Royal Society of London. 72 (477–486): 357–370. doi:10.1098/rspl.1903.0062. ISSN 0370-1662.
- "Library and Archive Catalogue". Royal Society. Retrieved 1 November 2010.[permanent dead link]
- "Medical lessons from World War I underscore need to keep developing antimicrobial drugs". MinnPost. 2014-11-11. Archived from the original on 30 January 2016. Retrieved 8 September 2017.
- USAMRMC: 50 Years of Dedication to the Warfighter 1958–2008 (PDF). U.S. Army Medical Research & Material Command (2008). 2008. p. 5. ASIN B003WYKJNY. Archived from the original (PDF) on 2013-02-14. Retrieved 2013-03-27.
- Felix A, Pitt RM (July 1934). "A New Antigen of B. Typhosus". The Lancet. 224 (5787): 186–191. doi:10.1016/S0140-6736(00)44360-6.
- Craigie J (1957-11-01). "Arthur Felix, 1887-1956". Biographical Memoirs of Fellows of the Royal Society. 3: 53–79. doi:10.1098/rsbm.1957.0005.
- "Typhoid Fever". Center for Emerging and Re-emerging Infectious Diseases. University of Washington. Retrieved 2019-12-08.
- "TYPHOID OR DRAIN FEVER, AND HOW TO PREVENT ITS SPREADING". The Warwick Examiner and Times. 6 April 1878. Retrieved 13 April 2020.
- Darby E (1983). The cult of the Prince Consort. Nicola Smith. New Haven: Yale University Press. ISBN 0-300-03015-0. OCLC 10432279.
- Matthew HC (September 2004). "Edward VII (1841–1910)". Oxford Dictionary of National Biography (online ed.). Oxford University Press (published May 2006). doi:10.1093/ref:odnb/32975. Archived from the original on 2016-03-02. (Subscription or UK public library membership required.)
- "Nicholas II - At the Court of the Last Tsar - Chapter 1, Part 2, The Empress Alexandra". www.alexanderpalace.org. Retrieved 2021-06-21.
- Dennis B (2011-09-29). "Willie Lincoln's death: A private agony for a president facing a nation of pain". The Washington Post. ISSN 0190-8286. Archived from the original on 2017-04-01. Retrieved 2017-03-12.
- "A History of Stanford". Stanford University. Retrieved 4 July 2018.
- Ruggles E (1944). Gerard Manley Hopkins: A Life. Norton.
- Scott BF (23 September 1910). "Scott, Henry James Herbert (1858–1910)". Biography – Henry James Herbert Scott. Australian Dictionary of Biography. National Centre of Biography, Australian National University. Archived from the original on 2011-02-21.
- "Straw for Silence". The Spectator. Vol. 203. F.C. Westley. 1959. ISSN 0038-6952. OCLC 1766325. Retrieved March 16, 2011.
- Hakaru Hashimoto#Biography
- Appiah GD, Chung A, Bentsi-Enchill AD, Kim S, Crump JA, Mogasale V, et al. (June 2020). "Typhoid Outbreaks, 1989-2018: Implications for Prevention and Control". The American Journal of Tropical Medicine and Hygiene. 102 (6): 1296–1305. doi:10.4269/ajtmh.19-0624. PMC 7253085. PMID 32228795.
- "Disease & Death in Early America: Tully Area Historical Society". tullyhistoricalsociety.org. Retrieved 2021-06-29.
- "Emsworth Oysters". Emsworth Business Association. 10 February 2019. Archived from the original on 3 February 2016.
- Bulstrode HT (1903). Dr. H. Timbrell Bulstrode's report to the Local Government Board upon alleged oyster-borne enteric fever and other illness following the mayoral banquets at Winchester and Southampton, and upon enteric fever occurring simultaneously elsewhere and also ascribed to oysters (Report). London: HMSO. p. 1.
- "Typhoid left city 'under siege'". 2008-06-26. Retrieved 2021-06-29.
- Lunguya O, Lejon V, Phoba MF, Bertrand S, Vanhoof R, Verhaegen J, et al. (2012-11-15). Ryan ET (ed.). "Salmonella typhi in the democratic republic of the congo: fluoroquinolone decreased susceptibility on the rise". PLOS Neglected Tropical Diseases. 6 (11): e1921. doi:10.1371/journal.pntd.0001921. PMC 3499407. PMID 23166855.
- World Health Organization, Newsroom (January 31, 2018). "Typhoid: Fact Sheet". Retrieved June 27, 2021.
- Public Health Agency of Canada (2010). "Pathogen Safety Data Sheets: Infectious Substances – Salmonella enterica spp". Retrieved June 28, 2021.
- Centers for Disease Control and Prevention (March 30, 2021). "Typhoid and Paratyphoid Fever: Information for Health Professionals". Retrieved June 27, 2021.
- National Health Service (June 18, 2018). "Typhoid Fever: Overview". Retrieved June 27, 2021.
- Adler R, Mara E (2016). Typhoid Fever: a history. Jefferson, North Carolina: McFarland & Company Inc. ISBN 978-0-7864-9781-2.
- GBD 2017 Typhoid and Paratyphoid Collaborators (February 18, 2019). "The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017". The Lancet Infectious Diseases. 19 (14): 369–381. doi:10.1016/S1473-3099(18)30685-6. PMC 6437314. PMID 30792131.